9.24
+0.47(+5.36%)
Currency In USD
| Previous Close | 8.77 |
| Open | 8.99 |
| Day High | 9.5 |
| Day Low | 8.7 |
| 52-Week High | 9.5 |
| 52-Week Low | 0.78 |
| Volume | 2.17M |
| Average Volume | 3.86M |
| Market Cap | 659.35M |
| PE | -6.2 |
| EPS | -1.49 |
| Moving Average 50 Days | 4.21 |
| Moving Average 200 Days | 2.48 |
| Change | 0.47 |
If you invested $1000 in Ventyx Biosciences, Inc. (VTYX) since IPO date, it would be worth $439.58 as of November 11, 2025 at a share price of $9.24. Whereas If you bought $1000 worth of Ventyx Biosciences, Inc. (VTYX) shares 3 years ago, it would be worth $348.42 as of November 11, 2025 at a share price of $9.24.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors
GlobeNewswire Inc.
Oct 22, 2025 8:02 PM GMT
VTX3232 demonstrated significant reductions in cardiovascular risk factors, with additional benefits when combined with semaglutide VTX3232 monotherapy achieved ~80% reduction in hsCRP within the first weekVTX3232 monotherapy reduced IL-6 levels at W
Ventyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson’s Disease
GlobeNewswire Inc.
Jun 17, 2025 11:00 AM GMT
The study met its primary goal of establishing safety and tolerability of VTX3232 in patients with early-stage Parkinson’s disease CSF and plasma exposures reinforce VTX3232’s potential as a once-daily oral therapy for neurodegenerative diseases VTX3
Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference
GlobeNewswire Inc.
May 28, 2025 12:00 PM GMT
SAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and ne